{"url_path":"/sec/gtbp/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-023346-index.html","accession_number":"0001493152-26-023346","cik":"0000109657","ticker":"GTBP","issuer_name":"GT Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/109657/0001493152-26-023346-index.html","primary_entity_key":"0000109657","primary_entity_name":"GT Biopharma, Inc."},"word_count":1025,"has_tables":true,"body_markdown":"false\n--12-31\nQ1\n0000109657\n\n0000109657\n\n2026-01-01\n2026-03-31\n\n0000109657\n\n2026-05-08\n\n0000109657\n\n2026-03-31\n\n0000109657\n\n2025-12-31\n\n0000109657\n\nGTBP:SeriesLPreferredStockMember\n\n2026-03-31\n\n0000109657\n\nGTBP:SeriesLPreferredStockMember\n\n2025-12-31\n\n0000109657\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-12-31\n\n0000109657\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesCPreferredStockMember\n\n2025-12-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nGTBP:SeriesLPreferredStockMember\n\n2025-12-31\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0000109657\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0000109657\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesCPreferredStockMember\n\n2024-12-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nGTBP:SeriesLPreferredStockMember\n\n2024-12-31\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0000109657\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0000109657\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0000109657\n\n2024-12-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesCPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nGTBP:SeriesLPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesCPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nGTBP:SeriesLPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesCPreferredStockMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nGTBP:SeriesLPreferredStockMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesCPreferredStockMember\n\n2025-03-31\n\n0000109657\n\nus-gaap:PreferredStockMember\nGTBP:SeriesLPreferredStockMember\n\n2025-03-31\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0000109657\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0000109657\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0000109657\n\n2025-03-31\n\n0000109657\n\nGTBP:SeriesLConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:SeriesLConvertiblePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nGTBP:PurchaseAgreementMember\n\n2025-05-14\n2025-05-14\n\n0000109657\n\nGTBP:PurchaseAgreementMember\n\n2025-05-14\n\n0000109657\n\n2025-02-26\n2025-02-26\n\n0000109657\n\n2025-02-26\n\n0000109657\n\nus-gaap:CommonStockMember\n\n2025-02-26\n\n0000109657\n\nGTBP:InducementWarrantsMember\n\n2025-02-26\n\n0000109657\n\nGTBP:SeriesAInducementWarrantsMember\n\n2025-02-26\n\n0000109657\n\nGTBP:SeriesBInducementWarrantsMember\n\n2025-02-26\n\n0000109657\n\nGTBP:SeriesLPreferredStockMember\nGTBP:MayTwoThousandTwentyFivePrivatePlacementMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:SeriesLPreferredStockMember\nGTBP:MayTwoThousandTwentyFivePrivatePlacementMember\n\n2026-03-31\n\n0000109657\n\nGTBP:SeriesLPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:WarrantsMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:SecuritiesPurchaseAgreementMember\nGTBP:SeriesLTenPercentConvertiblePreferredStockMember\nGTBP:CommonWarrantsMember\n\n2025-05-31\n\n0000109657\n\nGTBP:SecuritiesPurchaseAgreementMember\nGTBP:SeriesLTenPercentConvertiblePreferredStockMember\nGTBP:VestingWarrantsMember\n\n2025-05-31\n\n0000109657\n\nGTBP:SecuritiesPurchaseAgreementMember\nGTBP:VestingWarrantsMember\n\n2025-05-31\n\n0000109657\n\nGTBP:GreenshoeRightsMember\n\n2025-05-31\n\n0000109657\n\nGTBP:CommonWarrantsMember\n\n2026-03-31\n\n0000109657\n\nGTBP:OmnibusIncentivePlanMember\n\n2022-04-01\n2022-04-30\n\n0000109657\n\nGTBP:OmnibusIncentivePlanMember\nsrt:MaximumMember\n\n2022-04-01\n2022-04-30\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeOneMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeOneMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeTwoMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeTwoMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeThreeMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeThreeMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeFourMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeFourMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeFiveMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeFiveMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeSixMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeSixMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeSevenMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeSevenMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeEightMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeEightMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeNineMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeNineMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeTenMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\nGTBP:RangeTenMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0000109657\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:RangeOneMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:RangeOneMember\n\n2026-03-31\n\n0000109657\n\nGTBP:RangeTwoMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:RangeTwoMember\n\n2026-03-31\n\n0000109657\n\nGTBP:RangeThreeMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:RangeThreeMember\n\n2026-03-31\n\n0000109657\n\nGTBP:RangeFourMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:RangeFourMember\n\n2026-03-31\n\n0000109657\n\nGTBP:RangeFiveMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:RangeFiveMember\n\n2026-03-31\n\n0000109657\n\nGTBP:ZOneLLCMember\n\n2025-02-17\n2025-02-17\n\n0000109657\n\nGTBP:CobySilberfeinMember\n\n2025-07-08\n2025-07-08\n\n0000109657\n\nGTBP:CobySilberfeinMember\n\n2025-07-09\n2025-07-09\n\n0000109657\n\nGTBP:CobySilberfeinMember\n\n2025-09-02\n2025-09-02\n\n0000109657\n\nGTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember\n\n2024-05-20\n2024-05-20\n\n0000109657\n\nGTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember\n\n2025-06-18\n2025-06-18\n\n0000109657\n\nGTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember\n\n2026-03-26\n2026-03-26\n\n0000109657\n\nGTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\n\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nGTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nsrt:MinimumMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nsrt:MaximumMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nGTBP:TwoThousandTwentyTwoMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nGTBP:TwoThousandTwentyFiveMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nGTBP:TwoThousandTwentySevenMember\n\n2016-07-18\n2016-07-18\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\n\n2024-05-13\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nGTBP:TwoThousandTwentyFiveMember\n\n2024-05-13\n2024-05-13\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\n\n2024-05-13\n2024-05-13\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nsrt:MinimumMember\n\n2024-05-13\n2024-05-13\n\n0000109657\n\nGTBP:TwoThousandSixteenPatentLicenseAgreementMember\nsrt:MaximumMember\n\n2024-05-13\n2024-05-13\n\n0000109657\n\nGTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember\n\n2021-03-26\n2021-03-26\n\n0000109657\n\nsrt:MinimumMember\nGTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember\n\n2021-03-26\n2021-03-26\n\n0000109657\n\nsrt:MaximumMember\nGTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember\n\n2021-03-26\n2021-03-26\n\n0000109657\n\nGTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember\n\n2024-11-18\n2024-11-18\n\n0000109657\n\nGTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000109657\n\nGTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember\n\n2025-01-01\n2025-03-31\n\n0000109657\n\nGTBP:TwoThousandTwentyFourGtbThreeSixFiveZeroClinicalTrialAgreementMember\n\n2026-03-31\n\n0000109657\n\nGTBP:AdvisoryAgreementMember\n\n2025-06-01\n2025-06-30\n\n0000109657\n\nGTBP:AdvisoryAgreementMember\n\n2025-06-30\n\n0000109657\n\n2025-11-20\n\n0000109657\n\nus-gaap:SubsequentEventMember\n\n2026-05-12\n\n0000109657\n\nus-gaap:SubsequentEventMember\n\n2026-05-08\n\n0000109657\n\nus-gaap:SubsequentEventMember\nGTBP:ClinicalTrialAgreementMember\n\n2026-04-03\n2026-04-03\n\n0000109657\n\nGTBP:AmendedAdvisoryAgreementMember\nus-gaap:SubsequentEventMember\n\n2026-04-01\n2026-12-31\n\n0000109657\n\nGTBP:AmendedAdvisoryAgreementMember\nus-gaap:SubsequentEventMember\n\n2026-04-01\n\n0000109657\n\nGTBP:AmendedAdvisoryAgreementMember\nus-gaap:SubsequentEventMember\n\n2026-04-01\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nGTBP:Segment\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n☒\n**Quarterly\nreport pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026.**\n\n \n\n☐\n**Transition\nreport pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**For\nthe transition period from __________ to ____________.**\n\n \n\n**Commission\nFile Number 001-40023**\n\n \n\n**GT\nBIOPHARMA, INC.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Delaware**\n \n**94-1620407**\n\n(State\nor other jurisdiction of incorporation or organization)\n \n(I.R.S.\nEmployer Identification Number)\n\n** **\n\n**N/A1**\n\n(Address\nof principal executive offices)\n\n \n\n**415-919-4040**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof Each Class**\n \n**Trading\nSymbol**\n \n**Name\nof exchange on which registered**\n\nCommon\nStock, $0.001 par value per share\n \nGTBP\n \nNasdaq\nCapital Market\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\nYes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer ☐\nAccelerated\nfiler ☐\n\nNon-accelerated\nfiler ☒\nSmaller\nreporting company ☒\n\nEmerging\ngrowth company ☐\n \n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 8, 2026, the registrant had 36,062,904 shares of common stock outstanding.\n\n \n\n**1**\nEffective as of July 1, 2024, the Company became a fully remote\ncompany. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act\nof 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Company’s\nprincipal executive offices may be directed to 505 Montgomery Street, 10th Floor, San Francisco, California 94111, or by email to auditcommittee@gtbiopharma.com.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**GT\nBIOPHARMA, INC.**\n\n**FORM\n10-Q**\n\n**For\nthe Three Months Ended March 31, 2026**\n\n**Table\nof Contents**\n\n \n\n \n \n \nPage\n\nPART\nI FINANCIAL INFORMATION"}